SiBone (NASDAQ:SIBN) CEO Laura Francis Sells 14,957 Shares

SiBone (NASDAQ:SIBN) CEO Laura Francis sold 14,957 shares of the stock in a transaction on Monday, May 18th. The shares were sold at an average price of $14.71, for a total value of $220,017.47. Following the completion of the sale, the chief executive officer owned 503,444 shares of the company’s stock, valued at $7,405,661.24. The trade was a 2.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

SiBone Stock Performance

NASDAQ SIBN opened at $14.82 on Thursday. The company has a quick ratio of 8.34, a current ratio of 9.99 and a debt-to-equity ratio of 0.20. SiBone has a twelve month low of $11.48 and a twelve month high of $21.89. The stock has a fifty day simple moving average of $13.36 and a 200 day simple moving average of $16.10. The company has a market capitalization of $657.27 million, a price-to-earnings ratio of -38.00 and a beta of 0.67.

SiBone (NASDAQ:SIBN) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.07. SiBone had a negative net margin of 8.10% and a negative return on equity of 9.56%. The firm had revenue of $52.59 million for the quarter, compared to the consensus estimate of $51.16 million. Sell-side analysts expect that SiBone will post -0.44 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on SIBN. TD Cowen reduced their price objective on shares of SiBone from $22.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, May 12th. Truist Financial reiterated a “buy” rating and set a $18.00 price target (down from $20.00) on shares of SiBone in a report on Tuesday, May 12th. Finally, Wall Street Zen downgraded SiBone from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $23.00.

Institutional Trading of SiBone

Several large investors have recently made changes to their positions in the company. Bank of America Corp DE grew its stake in shares of SiBone by 8.7% in the 1st quarter. Bank of America Corp DE now owns 419,473 shares of the company’s stock valued at $5,298,000 after buying an additional 33,688 shares during the period. ADAR1 Capital Management LLC acquired a new stake in shares of SiBone in the 1st quarter valued at about $159,000. Quantinno Capital Management LP grew its stake in shares of SiBone by 58.2% in the 1st quarter. Quantinno Capital Management LP now owns 29,475 shares of the company’s stock valued at $372,000 after buying an additional 10,848 shares during the period. First Light Asset Management LLC grew its stake in shares of SiBone by 6.4% in the 1st quarter. First Light Asset Management LLC now owns 5,353,190 shares of the company’s stock valued at $67,611,000 after buying an additional 320,286 shares during the period. Finally, Granahan Investment Management LLC grew its stake in shares of SiBone by 97.6% in the 1st quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company’s stock valued at $21,965,000 after buying an additional 858,942 shares during the period. 98.11% of the stock is currently owned by institutional investors and hedge funds.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.